What Next for Novus Therapeutics Incorporated (NASDAQ:NVUS) Stock After Decrease in Shorted Shares?

July 17, 2017 - By Linda Rogers

 What Next for Novus Therapeutics Incorporated (NASDAQ:NVUS) Stock After Decrease in Shorted Shares?

The stock of Novus Therapeutics Incorporated (NASDAQ:NVUS) registered a decrease of 1.07% in short interest. NVUS’s total short interest was 138,200 shares in July as published by FINRA. Its down 1.07% from 139,700 shares, reported previously. With 6,800 shares average volume, it will take short sellers 20 days to cover their NVUS’s short positions.

The stock increased 1.85% or $0.1 on July 17, reaching $5.5. About 25,734 shares traded. Novus Therapeutics Inc (NASDAQ:NVUS) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The company has market cap of $38.55 million. The Firm is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It currently has negative earnings. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program.

More notable recent Novus Therapeutics Inc (NASDAQ:NVUS) news were published by: Seekingalpha.com which released: “What’s Wrong With Tokai Pharmaceuticals?” on April 06, 2016, also Streetinsider.com with their article: “Form 3 Novus Therapeutics, Inc. For: Jul 10 Filed by: Kuwahara Jon” published on May 12, 2017, Prnewswire.com published: “Novus Therapeutics Announces Change in Management” on July 10, 2017. More interesting news about Novus Therapeutics Inc (NASDAQ:NVUS) were released by: Prnewswire.com and their article: “Otic Pharma Completes Merger with Tokai Pharmaceuticals” published on May 10, 2017 as well as Prnewswire.com‘s news article titled: “Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635 …” with publication date: June 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: